MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

3.74 -3.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.65

Max

3.89

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
Winstmarge	-77.289
Werknemers	260
EBITDA	-3.2M -11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+15.38% upside

Dividenden
By Dow Jones
Volgende Winsten	12 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-15M 106M
Vorige openingsprijs	7.6
Vorige sluitingsprijs	3.74

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 jan 2026, 23:43 UTC

Marktinformatie

Gold Consolidates; May Face Technical Correction -- Market Talk

20 jan 2026, 23:42 UTC

Marktinformatie

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 jan 2026, 23:41 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 jan 2026, 23:29 UTC

Marktinformatie

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 jan 2026, 22:27 UTC

Acquisities, Fusies, Overnames

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 jan 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 jan 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 jan 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 jan 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 jan 2026, 22:18 UTC

Winsten

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 jan 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 jan 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 jan 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 jan 2026, 22:11 UTC

Acquisities, Fusies, Overnames

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 jan 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 jan 2026, 22:08 UTC

Acquisities, Fusies, Overnames

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 jan 2026, 22:07 UTC

Acquisities, Fusies, Overnames

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 jan 2026, 22:06 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 jan 2026, 22:00 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ESG Roundup: Market Talk

20 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

15.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD 15.38%

Hoogste 5.5 USD

Laagste 3.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.